Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873605 | 0.95 | MCHR1 (0.54) | MCHR1RECQLSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5873534 | 0.80 | MCHR1 (0.56) | MCHR1SMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL5873663 | 0.80 | MCHR1 (0.63) | MCHR1SMN1; SMN2MAPT | |
| SCHEMBL5873615 | 0.79 | MCHR1 (0.61) | MCHR1 | |
| SCHEMBL6560080 | 0.79 | MCHR1 (0.54) | MCHR1SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL5873550 | 0.79 | MCHR1 (0.61) | MCHR1 | |
| SCHEMBL5873691 | 0.77 | KDM4E (0.47) | MCHR1RECQLSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5873634 | 0.76 | MCHR1 (0.75) | MCHR1HRH3 | |
| SCHEMBL5873541 | 0.74 | MCHR1 (0.55) | MCHR1SMN1; SMN2MAPT | |
| SCHEMBL5873704 | 0.74 | MCHR1 (0.62) | MCHR1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | claimed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | claimed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885RECQL 533/4885SMN1; SMN2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.